Revolution Medicines (RVMD) shares have risen more than 130% following FDA approval in August 2026 of its pancreatic cancer drug Rasonque (daraxonrasib). To turn a $25,000 investment into $1 million, the company would need a market cap of roughly $1.6 trillion, compared with about $1.2 trillion for Eli Lilly. RBC Capital Markets estimates Rasonque's peak annual sales at $11.5 billion, which at the biotech industry's average price-to-sales ratio of 8.4 would imply a market cap near $97 billion. The article says the stock is probably unlikely to reach $1.6 trillion, but it could still deliver market-beating returns for long-term investors if pipeline candidates zoldonrasib and elironrasib win approvals. Billionaire Stanley Druckenmiller's Duquesne Family Office increased its stake by 26.5% in the third quarter of 2026.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
Revolution Medicinespharmaceuticalsvaluation
Open a keyword to see other news on the same topic.
Related news
- These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside Ahead
The article compares two lesser-known stocks, Revolution Medicines (RVMD) and Oruka Therapeutics (ORKA), which have both more than doubled this year and outpaced the Magnificent Seven. Revolution Medicines earned approval this year for Rasonque in metastatic pancreatic cancer, with a Phase 3 median overall survival of 13.2 months versus 6.7 months for cytotoxic chemotherapy, and some analysts project $20.8 billion in total peak revenue. Its average price target of $259.14 implies 35.7% upside, which the author considers too optimistic. Oruka has no approved medicine; its lead candidate ORKA-001, for plaque psoriasis, is in Phase 2a with encouraging results and could be dosed once or twice a year, while its $155 average target implies 95% upside. The author views Oruka as riskier than Revolution Medicines because ORKA-001 has not yet started Phase 3 trials.
- Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?
Duquesne Family Office, led by billionaire Stanley Druckenmiller, increased its Revolution Medicines stake by 26.5% in the second quarter, before the company's Rasonque won U.S. approval in August for certain pancreatic cancer patients. In a Phase 3 study, Rasonque achieved median overall survival of 13.2 months versus 6.7 months for chemotherapy, and some estimates project it could generate $15.1 billion in revenue by 2034 from pancreatic cancer alone. Some estimates put the number of U.S. patients diagnosed annually with metastatic pancreatic cancer at 55,000, with about 19,000 moving on to second-line treatment; assuming a roughly 30% net discount, the opportunity is nearly $3 billion a year. With a market cap of about $40 billion that has fallen since approval, the author says that at a 12% required rate of return and a forward price-to-sales ratio of 4 by 2031, revenue would need to reach $17.62 billion in 2032 to justify the current valuation. The author says they would seriously consider investing if the market cap falls by another $5 billion, citing clinical, regulatory and biotech volatility risks.
- Should You Buy Royalty Pharma Stock Before Nov. 4?
Royalty Pharma (RPRX) will report Q3 2026 earnings pre-market on Nov. 4. Shares fell in September after a major setback with one of its drug candidates and have since rebounded toward their 52-week high. Analysts forecast 8.7% sales growth and essentially zero earnings growth for the quarter ended Sept. 30, though forecasts have been revised upward since August, when royalty receipts grew 14%. The article says the company's results are seen as “lumpy” due to one-time milestone payments, and updates on JNJ-4804 and daraxonrasib, or underwhelming results with Novartis's pelacarsen, could influence the market reaction. The stock trades at around 12 times forward adjusted earnings, and the article suggests its valuation could move toward a multiple in line with larger, more established biotech stocks if earnings growth becomes steadier.
- 3 Dirt Cheap Dividend Stocks to Buy Hand Over Fist
The article argues that Pfizer, T. Rowe Price and Verizon look undervalued because the market is overreacting to their headwinds, while the S&P 500 trades at 23.5 times earnings with a 1.1% yield. Pfizer trades at 9.6 times forward earnings and offers a 5.6% dividend yield with a payout ratio just under 60%, though revenue and earnings have declined since 2022 and patent expirations such as Eliquis are pressuring shares. T. Rowe Price has a 5% forward dividend yield, a 40-year record of consecutive dividend growth and trades at 10 times forward earnings, and its pivot toward ETFs could soften the impact of a market downturn. Verizon added 550,000 net customer additions in mobility and broadband in the second quarter of 2026, but its shares have slumped on concerns about SpaceX's satellite services, and it has a 6.2% forward dividend yield at less than 9 times forward earnings.
- AstraZeneca offers compelling risk-reward into 2027 pipeline readouts, says JPMorgan
JPMorgan says AstraZeneca (LSE:AZN, NYSE:AZN) offers a compelling risk-reward opportunity ahead of late-stage readouts in 2027, which could collectively unlock more than $20 billion in non-risk-adjusted peak sales. Key studies include laroprovstat, Farxiga combinations, Datroway, puxi-sam, camizestrant and saruparib. The AVANZAR trial of Datroway has moved to Q1 2027 from Q4 2026 because progression-free survival events have not yet accumulated; JPMorgan says this could raise confidence in success, particularly in patients with the TROP2 biomarker. The stock trades at around 15 times 2027 earnings, broadly in line with European pharma, and the broker sees this as attractive given expected core earnings growth of around 10% over 2027-2030, roughly 40% ahead of the sector.
- ORIC Pharmaceuticals (ORIC) Stock Sees Modest Fair Value Lift On Trial Catalyst Optimism
The modeled fair value for ORIC Pharmaceuticals moved from US$20.67 to US$21.93, a small change tied to analyst views on enozertinib and rinzimetostat. Several firms, including Stifel, JPMorgan and H.C. Wainwright, raised price targets into a US$18 to US$27 range, with JPMorgan describing enozertinib as an underappreciated driver. BTIG and Leerink initiated coverage with US$26 targets, while one analyst noted the stock was down 5% at US$12.89 in morning trading on the day of the lung cancer data update. The fair value model also changed the net profit margin assumption from 17.25% to 15.91% and the future P/E from 753.08x to 971.94x.
Related markets
Latest news
- Nvidia responds to report Jensen Huang was target of Chinese asset, says diversion allegations were 'investigated and debunked'
Nvidia has rejected a New York Times report that US intelligence agencies monitored Alice Huang, who is linked to Singapore-based cloud provider Megaspeed and is close to CEO Jensen Huang, over suspicions she could be a Chinese intelligence asset. According to the report, the agencies feared she could help Beijing obtain information from Nvidia and gain access to President Donald Trump through Huang. In a statement to CNBC, Nvidia said Megaspeed is one of its regional cloud customers, that Huang's contact with its officials is routine, and that customers do not get access to trade secrets or sensitive national security information. The company said allegations that Megaspeed helped evade US export controls were 'thoroughly investigated and debunked last year', and that the US government would let it know if it considered anyone a threat. Nvidia also noted that Washington cleared H200 chip shipments to China earlier this year, but Chinese regulators blocked imports, leading to about $4.5 billion in write-offs of China-tuned AI chips last year.
- Wall Street's top analysts are loving Microsoft's Q1 results
Microsoft reported first-quarter earnings of $4.89 per share on revenue of $92.28 billion, above Bloomberg consensus estimates of $4.73 and $90.63 billion, though the stock fell more than 1% after the bell. Azure revenue grew 48% year over year to $33.17 billion, which analysts highlighted as the strongest part of the report. TD Cowen raised its fiscal 2027 Azure growth estimate to 48% from 43% and its price target to $650 from $625, while Cantor lifted its target to $630 from $608 and Citizens raised its target to $625 from $550. Citizens also noted that consumer business revenue fell 3%, while BofA reaffirmed its rating and raised its price target to $630 from $600.
- Why Is PepsiCo Stock Falling, and Is It a Buying Opportunity?
PepsiCo (PEP) shares are down about 14% over the past six months. Although third-quarter results were not bad, management cut full-year adjusted EPS guidance as North American sales recover more slowly than expected. The company had cut prices on core brands like Lay's and Doritos by up to 15% to attract value-sensitive consumers, but plans modest price increases in 2027, while inflation, tariffs and higher transportation costs add pressure. The article notes strong international performance and a lower guidance bar for next quarter, and says the stock's valuation, around 15 times forward earnings and a price-to-sales ratio slightly under 2, suggests it is fairly priced. As a Dividend King with at least 50 consecutive years of dividend increases and a yield above 4%, it is described as a defensive consumer goods stock for income-focused or patient investors.
- Global AI Data Center Market Size, Share, Trends, and Forecast 2026-2036 | Revenue to Reach USD 2.75 Trillion as Hyperscale Investment, AI Inference, and Edge Deployments Accelerate
The report projects the global AI data center market to grow from USD 354.2 billion in 2026 to USD 2.75 trillion by 2036, a CAGR of 22.5% over 2026-2036. Growth is driven by generative AI and large language models, demand for GPU computing, investment from hyperscale cloud providers, and AI-as-a-Service, while challenges include power grid limits, high capital requirements and energy availability. Hardware is expected to hold the largest share in 2026 and services the highest CAGR, with hyperscale facilities leading in share and edge AI data centers growing fastest. North America leads in 2026 and Asia-Pacific is projected to grow fastest, while NVIDIA, Cisco, Intel, Dell, Equinix and Digital Realty are named as key competitors.
- AI Cloud Stocks Fall as Big Tech Capex Comes in Light: Fastly Sinks 6%, Oracle and Nebius Drop 3%
AI cloud stocks fell as Microsoft and Alphabet reported capital spending below Wall Street expectations: Microsoft reported $45.2 billion against a $50.7 billion consensus, and Alphabet reported $51.36 billion against $55.09 billion. Microsoft CFO Amy Hood said some expected third-party capacity deliveries were delayed, without naming a supplier, but still expects capital spending above $50 billion next quarter and about $170 billion for the calendar year. Because Microsoft buys computing capacity from providers such as Nebius and CoreWeave, the delays raise questions about how quickly their revenue will grow. Fastly (FSLY) fell 6% to $25.43, Oracle (ORCL) dropped 3% to $140.57 and Nebius (NBIS) dropped 3% to $177.56, while CoreWeave was roughly flat at $64. Hood said customer demand continues to exceed available supply.
- Alphabet shares plunge as search weakness overshadows Google Cloud growth
Alphabet (GOOG) shares plunged more than 11% on Thursday after third-quarter revenue and earnings per share missed expectations, with search revenue rising 12% against a 15% forecast and YouTube advertising reaching $11.2 billion versus $11.4 billion expected. Google Cloud revenue grew 103%, beating expectations of 93%, with operating margins of 36.2% and backlog rising to $561 billion from $510 billion. Bank of America kept its rating but cut its price target to $380 from $430, while UBS lowered its target to $332 from $380 and kept a Neutral rating, questioning whether external TPU sales will lift profitability as cloud margins were flat quarter over quarter. Investors remain concerned about spending, as Alphabet kept its 2026 capital expenditure outlook at $195 billion to $205 billion and recorded negative free cash flow for a second straight quarter, more than $9 billion in the red. Kathleen Brooks of XTB said the main concern for investors is weaker-than-expected advertising and search results.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.